CMS Proposes Extending Medicare Drug Price Negotiations to 2029, Pressuring Big Pharma Revenue
The Centers for Medicare and Medicaid Services proposed a rule extending Medicare drug price negotiations to drugs entering their first negotiation cycle from 2029, deepening the long-term revenue pressure on pharmaceutical companies.
What CMS proposed and why it matters
The Centers for Medicare and Medicaid Services published a proposed rule establishing the framework for Medicare drug price negotiations covering drugs entering the negotiation cycle from 2029 onward. This extends the timeline initially set by the Inflation Reduction Act, which authorised Medicare to negotiate directly with pharmaceutical companies on selected high-spend drugs, and makes clear that the program will not be a one-time exercise.
Under the IRA, the first round of negotiations covered 10 drugs selected in 2023 for 2026 pricing. The proposed rule for 2029 eligibility signals that CMS intends the program to grow steadily in scope, with more drugs added to the negotiation list each year. Drugs with no generic or biosimilar competition and high Medicare spend are the primary targets.
Why this is a structural headwind for pharma revenue
The drug-pricing negotiation program imposes mandatory discounts on Medicare Part D drugs selected for the program. Companies that refuse to negotiate face a tax on total US drug revenues that effectively makes participation compulsory. The negotiated price applies to Medicare beneficiaries but does not directly cap commercial insurance pricing; however, it sets a reference point that can influence broader contracting.
The 2029 timeline matters because it gives pharmaceutical companies a longer horizon over which to model revenue from drugs currently in development or early commercialisation. A drug approved in 2025 could face price negotiation as soon as 2029, compressing the years at which it earns uncapped revenue. That compression reduces the expected net present value of pipeline drugs.
Which pharma companies are most exposed, and why
Merck has the largest near-term exposure. Keytruda, the world's best-selling cancer drug, is already in the 2026 negotiation cycle. Additional Merck drugs face eligibility in subsequent cycles. A rule extending the program to 2029 adds certainty that the program will continue, reducing any optimism that it might be rescinded.
Eli Lilly faces long-term GLP-1 risk. Mounjaro and Zepbound are growing toward the Medicare spend thresholds that trigger negotiation eligibility. A permanent negotiation framework means these drugs will eventually be negotiated, capping price upside in Medicare.
AbbVie is exposed through its immunology portfolio. Humira's biosimilar erosion is already pressuring revenue, and its successor drugs Skyrizi and Rinvoq are growing toward Medicare spend levels that would make them targets for future negotiation cycles.
What to watch
The proposed rule is subject to a public comment period before finalisation. Watch for industry comments from PhRMA and any legal challenges, following the pattern of litigation against earlier IRA negotiation authority. The number of drugs added to the 2029 negotiation list will be the concrete financial measure: each additional drug means incremental Medicare revenue at a mandated discount rather than market price.
Sources
Frequently asked questions
What is the CMS drug price negotiation program?
Under the Inflation Reduction Act, Medicare is authorised to negotiate directly with drug companies on selected high-spend drugs. The first negotiated prices take effect in 2026, and the proposed rule extends the program to drugs eligible from 2029.
Does a Medicare negotiated price affect what commercial insurance pays?
Not directly. The negotiated price applies only to Medicare Part D. However, it can serve as a reference point in commercial insurance contracting negotiations.
Which drugs are most at risk from the 2029 negotiation extension?
Drugs with high Medicare spending and no generic or biosimilar competition are the primary targets. Keytruda for Merck is already in the 2026 cycle; GLP-1 drugs for Eli Lilly and new immunology drugs for AbbVie are candidates for later cycles.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
One story is a data point. The pattern is the edge.
Reading one story at a time, you miss how the news adds up. Track MRK free and TradeTidings rolls every future headline into one clear positive, neutral or negative read, and alerts you the moment it turns.
Follow all 3 stocks in this story as one aggregated read with Pro.